Compare Organon & Co. Common Stock (OGN) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Wayfair Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Wayfair Inc trades at $104.22 (market cap $14.79B). The key difference: Wayfair Inc is far larger — about 4.1× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Wayfair Inc for 8 Days on average.
| OGN | W | |
|---|---|---|
Market Cap | $3.62B | $14.79B |
Volume | 2,892,999 | 1,870,669 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $119.05 |
52-Week Low | $5.70 | $57.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $11.04B | $17.13B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Wayfair (W) trades at $107.99, up 1.74% on the day, with a bullish technical signal from moving averages. The company reported revenue of $12.46B in 2025 but a net loss of $313M, with a negative net income margin of -2.49%. Analyst consensus is positive with a $114.13 price target, and recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook for Wayfair hinges on improving profitability amid competitive pressures. While revenue growth is steady, persistent losses and high debt-to-asset ratio of 95.11% pose risks. The stock offers upside to the consensus target but requires monitoring of cost management and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
